{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:42Z","timestamp":1786119582605,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/cad.0b013e32833b975b","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T05:52:44Z","timestamp":1277185964000},"page":"708-715","source":"Crossref","is-referenced-by-count":7,"title":["Combined phase I\/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma"],"prefix":"10.1097","volume":"21","author":[{"given":"Thomas M.","family":"Moehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Feneberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Dick","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly K.","family":"Golenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kropff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriet K.","family":"Khuageva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Hajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"von Broen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"Kastritis","year":"2009","journal-title":"Leukemia"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V98.13.3846","article-title":"Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy","volume":"98","author":"Moehler","year":"2001","journal-title":"Blood"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"R4-7-20210203","first-page":"389","article-title":"Immune modulation and control of neoplasia by adjuvant therapy","author":"Bicker","year":"1978"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnci\/87.12.935-a","article-title":"Antitumor activity of imexon","volume":"87","author":"Sagaster","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/86.3.228","article-title":"Sensitivity of multiple myeloma to imexon in the human tumor cloning assay","volume":"86","author":"Salmon","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood.V97.11.3544","article-title":"Induction of mitochondrial changes in myeloma cells by imexon","volume":"97","author":"Dvorakova","year":"2001","journal-title":"Blood"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1078-0432.CCR-1058-03","article-title":"Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent","volume":"10","author":"Evens","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10637-008-9149-9","article-title":"Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells","volume":"27","author":"Samulitis","year":"2009","journal-title":"Invest New Drugs"},{"key":"R10-7-20210203","first-page":"300","article-title":"Front BioSci","volume":"11","author":"Engel","year":"2006"},{"key":"R11-7-20210203","first-page":"403","article-title":"Immune modulation and control of neoplasia by adjuvant therapy","author":"Micksche","year":"1978"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.2006.08.9672","article-title":"Phase I trial of imexon in patients with advanced malignancy","volume":"25","author":"Dragovich","year":"2007","journal-title":"J Clin Oncol"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00280-006-0329-z","article-title":"Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines","volume":"59","author":"Scott","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1182\/blood-2009-02-207803","article-title":"Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival","volume":"113","author":"Nair","year":"2009","journal-title":"Blood"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32833b975b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:29:34Z","timestamp":1786040974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201008000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32833b975b","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}